Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017 -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/10/2019 | 10:32am EDT

Merck & Co., Inc. (MRK) is currently at $79.32, down $4.15 or 4.97%

-- Would be lowest close since May 31, 2019, when it closed at $79.21

-- On pace for largest percent decrease since Oct. 30, 2017, when it fell 6.06%

-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that first-line treatment with KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy demonstrated improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in a pooled analysis of a subgroup of patients with advanced nonsquamous and squamous non-small cell lung cancer (NSCLC) whose tumors do not express PD-L1 (tumor proportion score [TPS] <1%) from three randomized trials

-- Down 8.27% month-to-date

-- Up 3.81% year-to-date

-- Down 11.67% from its all-time closing high of $89.80 on Nov. 29, 2000

-- Up 14.82% from 52 weeks ago (Sept. 11, 2018), when it closed at $69.08

-- Down 8.73% from its 52 week closing high of $86.91 on Aug. 21, 2019

-- Up 16.02% from its 52 week closing low of $68.37 on Oct. 11, 2018

-- Worst performer in the DJIA today

-- Second worst performer in the S&P 500 today

-- Subtracted 28.14 points from the DJIA so far today

All data as of 10:05:18 AM

Source: Dow Jones Market Data, FactSet

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.14% 27219.52 Delayed Quote.16.68%
MERCK AND COMPANY -0.18% 82.61 Delayed Quote.8.11%
MERCK KGAA AG 1.71% 99.02 Delayed Quote.10.05%
MERCK LTD 0.67% 4324.05 End-of-day quote.37.27%
MRK HOLDINGS INC -1.17% 169 End-of-day quote.21.58%
NASDAQ 100 -0.31% 7892.954646 Delayed Quote.25.08%
NASDAQ COMP. -0.22% 8176.71293 Delayed Quote.23.50%
PROVIDENT FINANCIAL SERVICES, INC. 1.30% 25.78 Delayed Quote.6.84%
S&P 500 -0.07% 3007.39 Delayed Quote.19.97%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
09/13MERCK AND COMPANY : Ex-dividend day for
FA
09/10Merck Down Nearly 5%, on Pace for Largest Percent Decrease Since October 2017..
DJ
09/10MERCK AND : - Pivotal New Data from 's Broad Oncology Portfolio at ESMO 2019 Con..
AQ
09/10MERCK : Announces First Nine “Safer Childbirth Cities” Committed to ..
BU
09/10MERCK AND : Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) ..
BU
09/09MERCK AND : Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 ..
BU
09/08BERGENBIO : Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcent..
AQ
09/05MERCK : to Present at the Morgan Stanley 17th Annual Global Healthcare Conferenc..
BU
09/04MERCK FOUNDATION : Launches Five-Year Initiative to Reduce Disparities in HIV Ca..
BU
09/04MERCK AND : Gets Europe OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma
DJ
More news
Financials (USD)
Sales 2019 45 855 M
EBIT 2019 15 626 M
Net income 2019 10 923 M
Debt 2019 19 506 M
Yield 2019 2,66%
P/E ratio 2019 19,9x
P/E ratio 2020 16,5x
EV / Sales2019 5,04x
EV / Sales2020 4,69x
Capitalization 212 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 96,67  $
Last Close Price 82,61  $
Spread / Highest target 27,1%
Spread / Average Target 17,0%
Spread / Lowest Target 7,74%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY8.11%211 513
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
PFIZER-15.44%204 151
NOVARTIS18.45%200 777
NOVO NORDISK AS14.89%118 168